Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
RESEARCH TOOLSreports
IKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $4.20
Previous CloseN/A
Volume38.02K
Average Volume (3M)162.35K
Market Cap
$164.39M
Enterprise Value$8.45M
Total Cash (Recent Filing)-$379.56K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 27, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding69,362,440
10 Day Avg. Volume122,558
30 Day Avg. Volume162,347
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)812.56
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.63
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$8.00Price Target Upside237.55% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Inhibikase Therapeutics News
PremiumCompany Announcements
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals
PremiumCompany Announcements
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO
PremiumCompany Announcements
Inhibikase Adjusts and Terminates Stock Offering Agreement
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q3 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentIkT-001Pro is being developed to address unmet needs in pulmonary arterial hypertension, representing a significant opportunity despite being a rare disease.
Financial PerformanceThe company raised $110M in gross proceeds, which is expected to provide sufficient runway into 2027.
Regulatory ProgressFDA has agreed to an accelerated 505(b)(2) pathway, allowing IKT to leverage imatinib's existing approval for a potentially faster development process.
Bears Say
Analyst RatingAnalyst's rating downgraded to Neutral from Buy due to the company’s decision to halt further development of risvodetinib.
Clinical And Execution RisksThere is still execution and clinical risk over the medium to longer term for PAH treatment.
Clinical Trial ResultsRisvodetinib development paused following results from Phase 2 201 trial.
---
Ownership Overview
10.53% Insiders
0.13% Mutual Funds
66.08% Other Institutional Investors
19.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.12 and its highest was $4.20 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $164.39M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 2 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.48 by -$0.17.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 69,362,440 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.48. Following the earnings report the stock price went down -2.479%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
---
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.00 (237.55% Upside)
$8.00 (237.55% Upside)
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 10.6%
Last 30 Days ▼ 10.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.23%
12-Months-Change
Fundamentals
Return on Equity
-270.10%
Trailing 12-Months
Asset Growth
-75.52%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
---
IKT Stock 12 Month Forecast
Average Price Target
$8.00
▲(237.55% Upside)
Technical Analysis
Best Analysts Covering IKT
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+23.77%
reiterated a buy rating 4 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.77% per trade.
---